GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neoleukin Therapeutics Inc (NAS:NLTX) » Definitions » Price-to-Tangible-Book

Neoleukin Therapeutics (Neoleukin Therapeutics) Price-to-Tangible-Book : 0.10 (As of May. 03, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Neoleukin Therapeutics Price-to-Tangible-Book?

As of today (2024-05-03), Neoleukin Therapeutics's share price is $3.49. Neoleukin Therapeutics's Tangible Book per Share of Sep. 2023 for the quarter that ended in Sep. 2023 was $34.18. Hence, Neoleukin Therapeutics's Price to Tangible Book Ratio of today is 0.10.

The historical rank and industry rank for Neoleukin Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

NLTX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.1   Med: 2.01   Max: 4.98
Current: 0.1

During the past 11 years, Neoleukin Therapeutics's highest Price to Tangible Book Ratio was 4.98. The lowest was 0.10. And the median was 2.01.

NLTX's Price-to-Tangible-Book is not ranked
in the Biotechnology industry.
Industry Median: 2.71 vs NLTX: 0.10

A closely related ratio is called PB Ratio. As of today, Neoleukin Therapeutics's share price is $3.49. Neoleukin Therapeutics's Book Value per Sharefor the quarter that ended in Sep. 2023 was $34.18. Hence, Neoleukin Therapeutics's P/B Ratio of today is 0.10.


Neoleukin Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Neoleukin Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neoleukin Therapeutics Price-to-Tangible-Book Chart

Neoleukin Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.70 3.32 3.12 1.43 0.23

Neoleukin Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.26 0.23 0.37 0.46 0.46

Competitive Comparison of Neoleukin Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Neoleukin Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neoleukin Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neoleukin Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Neoleukin Therapeutics's Price-to-Tangible-Book falls into.



Neoleukin Therapeutics Price-to-Tangible-Book Calculation

Neoleukin Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Sep. 2023 )
=3.49/34.177
=0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Neoleukin Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Neoleukin Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Neoleukin Therapeutics (Neoleukin Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
188 East Blaine Street, Suite 450, Seattle, WA, USA, 98102
Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The firm generates immunotherapies using de novo protein design technology. It uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefits over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises NL-201, which is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.
Executives
Baker Bros. Advisors Lp 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Sean Michael Smith officer: Principal Accounting Officer C/O NEOLEUKIN THERAPEUTICS, INC., 188 E. BLAINE STREET, SUITE 450, SEATTLE WA 98102
Priti Patel officer: Chief Medical Officer C/O NEOLEUKIN THERAPEUTICS, INC., 188 EAST BLAINE STREET, #450, SEATTLE WA 98102
Erin Lavelle director C/O ALDER BIOPHARMACEUTICALS, INC., 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Donna Cochener officer: General Counsel, SVP Legal C/O NEOLEUKIN THERAPEUTICS, INC., 188 EAST BLAINE STREET, SUITE 450, SEATTLE WA 98102
Rohan Palekar director 201 SPEAR STREET, THIRD FLOOR, SAN FRANCISCO CA 94105
Jonathan G Drachman director, officer: See Remarks 21823 30TH DRIVE SE, BOTHELL WA 98021
Carl Walkey officer: Senior Vice President C/O NEOLEUKIN THERAPEUTICS, INC., 360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102
Robert Ho officer: Chief Financial Officer 360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102
Holly Vance officer: General Counsel C/O NEOLEUKIN THERAPEUTICS, INC., 360-1616 EASTLAKE AVENUE E., SEATTLE WA 98102
Martin Babler director C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Erin M. Lavelle director 360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102
Redmile Group, Llc 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Jeremy Green 10 percent owner 45 W. 27TH STREET, FLOOR 11, NEW YORK NY 10001
Sarah B. Noonberg director 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080

Neoleukin Therapeutics (Neoleukin Therapeutics) Headlines

From GuruFocus